Introduction
Problem
Solution
Business Model
Market
Competition
Success To Date
Press
Press Releases and Articles
- GlobeNewswire
O2 RegenTech Receives $600,000 to Develop Oxygenating Wound Treatments - TechOhio
O2 RegenTech Helping Heal Wounds - The University of Akron
O2 RegenTech receives funding to support pre-clinical development - Crain's Cleveland Business
O2 RegenTech, a startup out of University of Akron, is making a name for itself
Public Grant Summaries
- NSF SBIR Phase I Grant
SBIR Phase I: Tunable Oxygenating Biopolymer Hydrogel Dressings for Chronic Wound Care - NIH SBIR Phase I Grant
OXAID: Oxygenating Hydrogel for Diabetic Wound Care
Scientific Publications
- Wijekoon et al., 2013
Fluorinated Methacrylamide Chitosan Hydrogel Systems as Adaptable Oxygen Carriers for Wound Healing - Patil et al., 2016
Fluorinated Methacrylamide Chitosan Hydrogels Enhance Collagen Synthesis in Wound Healing Through Increased Oxygen Availability - Patil et al., 2017
Fluorinated Methacrylamide Chitosan Sequesters Reactive Oxygen Species to Relieve Oxidative Stress While Delivering Oxygen - Akula et al., 2017
Fluorinated Methacrylamide Chitosan Hydrogels Enhance Cellular Wound Healing Processes - Patil et al., 2018
Fluorinated Methacrylamide Chitosan Hydrogel Dressings Enhance Healing in an Acute Porcine Wound Model - Patil et al., 2019
Fluorinated Methacrylamide Chitosan Hydrogel Dressings Improve Regenerated Wound Tissue Quality in Diabetic Wound Healing
Team
The Opportunity
Use of Proceeds
If the offering's maximum amount of $612,000 is raised:
Use | Value | % of Proceeds |
---|---|---|
Product Development | $214,200 | 35.0% |
Regulatory Affairs | $61,200 | 10.0% |
Operations & Payroll | $153,612 | 25.1% |
Biocompatibility Testing | $153,000 | 25.0% |
Intermediary fees | $29,988 | 4.9% |
Terms
This number includes all funds raised by the Company in this round on Netcapital. This is an offering of Common Shares, under registration exemption 4(a)(6), in O2 REGENTECH LLC dba O2 RegenTech. This offering must reach its target of at least $10,000 by its offering deadline of April 1, 2025 at 11:59pm ET. If this offering does not reach its target by the offering deadline, then your money will be refunded.
If the offering is successful at raising the maximum amount, then the company’s implied valuation after the offering (sometimes called its post-money valuation) will be:
Financials
O2 RegenTech’s official name is O2 REGENTECH LLC, so that’s the name that appears in the statements below.
These financial statements have been reviewed by an independent Certified Public Accountant.
SEC Filings
The Offering Statement is a formal description of the company and this transaction. It’s filed with the SEC to comply with the requirements of exemption 4(a)(6) of the Securities Act of 1933.
We’re also required to share links to each of the SEC filings related to this offering with investors.
Understand the Risks
Be sure to understand the risks of this type of investment. No regulatory body (not the SEC, not any state regulator) has passed upon the merits of or given its approval to the securities, the terms of the offering, or the accuracy or completeness of any offering materials or information posted herein. That’s typical for Regulation CF offerings like this one.
Neither Netcapital nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.
The information contained herein includes forward-looking statements. These statements relate to future events or to future financial performance, and involve known and unknown risks, uncertainties, and other factors, that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will, materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
More Info
Updates
Ask a Question
Proofread your comment before submitting: once it's posted, you can’t edit or delete it. Investors are advised to review our Discussion Board Policy before submitting a comment. For the fastest help with the web site, email help@netcapital.com instead of commenting.
Looking to raise capital?
We can help turn your friends, family and customers into investors.
Interested in more investment opportunities?
Browse all offerings currently available.